Lantern Pharma Inc. — Director's Dealing 2025

Dec 22, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lantern Pharma Inc. (LTRN)
CIK: 0001763950
Period of Report: 2025-12-18

Reporting Person: Bhatia Kishor G. (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-12-18	Stock Option (Right to Buy)	$3.24	A	10000	Acquired	2035-12-17	Common Stock (10000)	Direct

Footnotes

F1: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing January 18, 2026.